JP2012506406A - 走化性因子阻害剤 - Google Patents

走化性因子阻害剤 Download PDF

Info

Publication number
JP2012506406A
JP2012506406A JP2011532646A JP2011532646A JP2012506406A JP 2012506406 A JP2012506406 A JP 2012506406A JP 2011532646 A JP2011532646 A JP 2011532646A JP 2011532646 A JP2011532646 A JP 2011532646A JP 2012506406 A JP2012506406 A JP 2012506406A
Authority
JP
Japan
Prior art keywords
stem cells
chemotactic factor
tissue
factor inhibitor
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011532646A
Other languages
English (en)
Japanese (ja)
Inventor
ベアトリス、ゴンザレス、ガルベス
フアン、カルロス、ロドリゲス、シマデビリャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Projech Science To Technology SL
Original Assignee
Projech Science To Technology SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Projech Science To Technology SL filed Critical Projech Science To Technology SL
Publication of JP2012506406A publication Critical patent/JP2012506406A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011532646A 2008-10-24 2009-10-23 走化性因子阻害剤 Pending JP2012506406A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08380303.1 2008-10-24
EP08380303 2008-10-24
PCT/EP2009/063985 WO2010046474A2 (fr) 2008-10-24 2009-10-23 Inhibiteurs chimiotactiques

Publications (1)

Publication Number Publication Date
JP2012506406A true JP2012506406A (ja) 2012-03-15

Family

ID=42022606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011532646A Pending JP2012506406A (ja) 2008-10-24 2009-10-23 走化性因子阻害剤

Country Status (3)

Country Link
EP (1) EP2355840A2 (fr)
JP (1) JP2012506406A (fr)
WO (1) WO2010046474A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
JP2007176814A (ja) * 2005-12-27 2007-07-12 Yoshihiro Futamura 炎症性サイトカイン産生抑制作用を有するゼアキサンチン誘導体、それからなる食品製剤、化粧品、抗炎症剤

Also Published As

Publication number Publication date
WO2010046474A3 (fr) 2010-08-05
EP2355840A2 (fr) 2011-08-17
WO2010046474A2 (fr) 2010-04-29

Similar Documents

Publication Publication Date Title
EP2315781B1 (fr) Antagonistes specifiques du recepteur fgf-r4
CN102596998B (zh) 血管增殖病症的治疗
PL211786B1 (pl) Zastosowanie przeciwciała oraz polipeptydu
JP2003277293A (ja) 移植片拒絶反応抑制剤
NZ581637A (en) Antibodies to OPGL
JP5785550B2 (ja) 神経疾患の処置方法
TW202043276A (zh) 肝毒性之治療
US20150376281A1 (en) Use of NKG2D Inhibitors for Treating Cardiovascular and Metabolic Diseases, Such as Type 2 Diabetes
CN120305401A (zh) 用于肝病的治疗的组合物和方法
US20240050529A1 (en) Modulating lymphatic vessels in neurological disease
JP2007512348A (ja) 形質細胞の治療のためのノッチ経路干渉剤の使用
JP6198742B2 (ja) 肺高血圧症
JP6306768B2 (ja) 疼痛抑制物質のスクリーニング方法および疼痛の予防または治療用医薬組成物
JP6942356B2 (ja) 制御性ｔ細胞の活性化剤及びその使用
WO2009086952A2 (fr) Compositions de traitement de maladies articulaires dégénératives
JP2012506406A (ja) 走化性因子阻害剤
JP7458049B2 (ja) 自己免疫疾患治療剤
JP7828614B2 (ja) Ｔｍ４ｓｆ１９抑制剤及びその用途
TW202019482A (zh) Htlv-1關聯性脊髓病(ham)之治療或預防劑、及ham之治療方法
WO2025070749A1 (fr) Agent préventif ou thérapeutique pour les symptômes associés accompagnant une maladie induite par un trouble de la moelle épinière ou du cerveau
TWI887333B (zh) 失智症之預防或治療劑
US20250179157A1 (en) A-fabp antibodies for diagnosis and treatment of obesity-associated diseases
WO2017126655A1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter la douleur, et procédé de criblage pour la recherche d'une substance de prévention de la douleur utilisant le robo4
US20220233641A1 (en) Methods and Compositions for Treating Obesity and/or Skin Disorders
TW202542309A (zh) 用於調節Ｎａｖ１．８之組合物及方法

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120808